Potential Clinical Utility of CA-125 in Responsive but Persistent Large-Volume Ovarian Cancer Following Platinum-Based Chemotherapy:

By Markman M.   Kennedy A.   Kim J.  

Gynecologic Oncology, Vol. 83, Iss. 3, 2001-12 ,pp. : 593-595

Elsevier

Access to resources Recommend Favorite

Markers of response to platinum-based chemotherapy in lung cancer

By Barr Martin P   MacDonagh Lauren   O'Byrne Kenneth J  

Lung Cancer Management, Vol. 2, Iss. 3, 2013-06 ,pp. : 227-239

Future Medicine

Access to resources Recommend Favorite

Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy

By Lee C.K.   Pires de Miranda M.   Ledermann J.A.   Ruiz de Elvira M.-C.   Nelstrop A.E.   Lambert H.E.   Rustin G.J.S.   Trask C.W.L.  

European Journal of Cancer, Vol. 35, Iss. 5, 1999-05 ,pp. : 727-732

Elsevier

Access to resources Recommend Favorite

Long-term Prognosis Following Macroscopic Complete Response at Second-look Laparotomy in Advanced Ovarian Cancer Patients Treated with Platinum-based Chemotherapy

By Chiara S.   Lionetto R.   Campora E.   Oliva C.   Merlini L.   Bruzzi P.   Rosso R.   Conte P.F.  

European Journal of Cancer, Vol. 31, Iss. 3, 1995-01 ,pp. : 296-301

Elsevier

Access to resources Recommend Favorite

Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression

By                

International Journal of Oncology, Vol. 44, Iss. 5, 2014-01 ,pp. : 1736-1744

Spandidos Publications

Access to resources Recommend Favorite